These two genes are frequently mutated in cancers, with SMARCA4 mutations prevalent in small cell ovarian cancer and PBRM1 altered in renal cell carcinoma.45SMARCA4-mutated cancers may depend on SMARCA2 and are therefore susceptible to synthetic lethality with SMARCA2 inhibition. This evidence concerns the gene SMARCA4 and ovarian small cell carcinoma.